 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 August 2000 | Volume 133 Issue 4 | Pages 263-274
Background: Troglitazone promotes adipocyte differentiation in vitro and increases insulin sensitivity in vivo. Therefore, troglitazone may have therapeutic benefit in lipoatrophic diabetes.
Objective: To determine whether troglitazone ameliorates hyperglycemia and hypertriglyceridemia or increases fat mass in lipoatrophic patients.
Design: Open-labeled prospective study.
Setting: United States and Canada.
Patients: 20 patients with various syndromes associated with lipoatrophy or lipodystrophy.
Intervention: 6 months of therapy with troglitazone, 200 to 600 mg/d.
Measurements: Levels of hemoglobin A1c, triglycerides, free fatty acids, and insulin; respiratory quotient; percentage of body fat; liver volume; and regional fat mass.
Results: In the 13 patients with diabetes who completed 6 months of troglitazone therapy, hemoglobin A1c levels decreased by a mean of 2.8% (95% CI, 1.9% to 3.7%; P < 0.001). In all 19 study patients, fasting triglyceride levels decreased by 2.6 mmol/L (230 mg/dL) (CI, 0.7 to 4.5 mmol/L [62 to 398 mg/dL]; P = 0.019) and free fatty acid levels decreased by 325 µmol/L (CI, 135 to 515 µmol/L; P = 0.035). The respiratory quotient decreased by a mean of 0.12 (CI, 0.08 to 0.16; P < 0.001), suggesting that troglitazone promoted oxidation of fat. Body fat increased by a mean of 2.4 percentage points (CI, 1.3 to 4.5 percentage points; P = 0.044). Magnetic resonance imaging showed an increase in subcutaneous adipose tissue but not in visceral fat. In one patient, the serum alanine aminotransferase level increased eightfold during the 10th months of troglitazone treatment but normalized 3 months after discontinuation of treatment. Liver biopsy revealed an eosinophilic infiltrate, suggesting hypersensitivity reaction as a cause of hepatotoxicity.
Conclusion: Troglitazone therapy improved metabolic control and increased body fat in patients with lipoatrophic diabetes. The substantial benefits of troglitazone must be balanced against the risk for hepatotoxicity, which can occur relatively late in the treatment course.
Author and Article Information
From National Institute of Diabetes and Digestive and Kidney Diseases and Clinical Center, National Institutes of Health, and National Cancer Institute, Bethesda, Maryland.
Acknowledgments: The authors thank Dr. Phillip Gorden for advice, encouragement, and support and Drs. Oksana Gavrilova, Monica Skarulis, Susan Phillips, and Karim Calis for valuable discussion. They also thank Craig Cochran, RN; Joy Jones, RN; Kathy O'Bunse, RN; Kathleen Beville, RN; and Delores Medina, RN, for excellent nursing support and the Fellows of the National Institutes of Health Inter-Institute Endocrine Training Program for their contribution in the care of the patients. The Respiratory Care Department at the Clinical Center performed the indirect calorimetry studies, and Bernice Marcus-Samuels performed the leptin assays. Finally, the authors thank Dr. Harvey Kushner for statistical advice and Ms. Esther Bergman for assistance in the coordination of the research trial.
Requests for Single Reprints: Elif Arioglu, MD, National Institutes of Health, Building 10, Room 9S213, Bethesda, MD 20892; e-mail, elif_arioglu@nih.gov.
Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Drs. Arioglu, Rother, Sumner, and Taylor, Ms. Duncan-Morin, Ms. Gottlieb, and Mr. Lieberman: Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9S213, Bethesda, MD 20892.
Ms. Sebring: National Institutes of Health, Clinical Center, Room B15234, Bethesda, MD 20892.
Dr. Herion: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9B16, 10 Center Drive, MSC1800, Bethesda, MD 20892.
Dr. Kleiner: Laboratory of Pathology, National Cancer Institute, Building 10, Room 2N212, Bethesda, MD 20892.
Dr. Reynolds: National Institutes of Health, Clinical Center, Building 10, Room 1C401, Bethesda, MD 20892.
Dr. Premkumar: National Institutes of Health, Clinical Center, Building 10, Room IC660, Bethesda, MD 20892.
Dr. Hoofnagle: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 31, Room 9A23, Bethesda, MD 20892.
Dr. Reitman: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 8N250, Bethesda, MD 20892.
Author Contributions: Conception and design: E. Arioglu, K.I. Rother, J. Reynolds, A. Premkumar, M.L. Reitman, S.I. Taylor.
Analysis and interpretation of the data: E. Arioglu, J. Duncan-Morin, N. Sebring, N. Gottlieb, J. Lieberman, D. Herion, D.E. Kleiner, A.E. Sumner, A. Premkumar, J. Hoofnagle, S.I. Taylor.
Drafting of the article: E. Arioglu, S.I. Taylor.
Critical revision of the article for important intellectual content: E. Arioglu, J. Duncan-Morin, N. Sebring, K.I. Rother, N. Gottlieb, J. Lieberman, D. Herion, D.E. Kleiner, A. Premkumar, A.E. Sumner, J. Hoofnagle, M.L. Reitman, S.I. Taylor.
Final approval of the article: E. Arioglu, J. Duncan-Morin, N. Sebring, N. Gottlieb, J. Lieberman, D. Herion, D.E. Kleiner, J. Reynolds, A. Premkumar, A.E. Sumner, J. Hoofnagle, M.L. Reitman, S.I. Taylor.
Provision of study materials or patients: E. Arioglu, K.I. Rother, D. Herion, D.E. Kleiner, J. Reynolds, A. Premkumar, S.I. Taylor.
Obtaining of funding: S.I. Taylor.
Administrative, technical, or logistic support: J. Duncan-Morin, N. Sebring, N. Gottlieb, S.I. Taylor.
Collection and assembly of data: E. Arioglu, J. Duncan-Morin, N. Sebring, K.I. Rother, N. Gottlieb, J. Lieberman, D. Herion, J. Reynolds, A. Premkumar. ARTICLE
Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  R. P. Naoumova, H. Kindler, L. Leccisotti, M. Mongillo, M. T. Khan, C. Neuwirth, M. Seed, P. Holvoet, J. Betteridge, and P. G. Camici Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined Hyperlipidemia: A Randomized, Double-Blind, Placebo-Controlled Study J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2051 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Milinkovic and E. Martinez Current perspectives on HIV-associated lipodystrophy syndrome J. Antimicrob. Chemother., July 1, 2005; 56(1): 6 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Martin and P. W. G. Mallon Therapeutic approaches to combating lipoatrophy: do they work? J. Antimicrob. Chemother., May 1, 2005; 55(5): 612 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Torriani and S. Grinspoon Racial differences in fat distribution: the importance of intermuscular fat Am. J. Clinical Nutrition, April 1, 2005; 81(4): 731 - 732. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sutinen, K. Kannisto, E. Korsheninnikova, R. M. Fisher, E. Ehrenborg, T. Nyman, A. Virkamaki, T. Funahashi, Y. Matsuzawa, H. Vidal, et al. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E941 - E949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Benavides and M. C Nahata Pharmacologic Therapy for HIV-Associated Lipodystrophy Ann. Pharmacother., March 1, 2004; 38(3): 448 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bays, L. Mandarino, and R. A. DeFronzo Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Lee Altered Glucose Metabolism in HIV-infected Patients Treated With HAART Journal of Pharmacy Practice, February 1, 2004; 17(1): 80 - 86. [Abstract] [PDF]
|
|
|
|
 |
|
 K. R. Owen, A. Stride, S. Ellard, and A. T. Hattersley Etiological Investigation of Diabetes in Young Adults Presenting With Apparent Type 2 Diabetes Diabetes Care, July 1, 2003; 26(7): 2088 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Fat Metabolism and Diabetes: 2003 American Diabetes Association Postgraduate Course Diabetes Care, July 1, 2003; 26(7): 2198 - 2203. [Full Text] [PDF]
|
|
|
|
|
|
M. K. S. Leow, C. L. Addy, and C. S. Mantzoros Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1961 - 1976. [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Savage, G. D. Tan, C. L. Acerini, S. A. Jebb, M. Agostini, M. Gurnell, R. L. Williams, A. M. Umpleby, E. L. Thomas, J. D. Bell, et al. Human Metabolic Syndrome Resulting From Dominant-Negative Mutations in the Nuclear Receptor Peroxisome Proliferator-Activated Receptor-{gamma} Diabetes, April 1, 2003; 52(4): 910 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hadigan, J. Rabe, G. Meininger, N. Aliabadi, J. Breu, and S. Grinspoon Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution Am. J. Clinical Nutrition, February 1, 2003; 77(2): 490 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. A. Walker, M. Kirschfink, and H. H. Peter Improvement of acquired partial lipodystrophy with rosiglitazone despite ongoing complement activation Rheumatology, February 1, 2003; 42(2): 393 - 394. [Full Text] [PDF]
|
|
|
|
 |
|
 I. K. Aronson and V. C. Fiedler Of Mice and Men: The Road to Understanding the Complex Nature of Adipose Tissue and Lipoatrophy Arch Dermatol, January 1, 2003; 139(1): 81 - 83. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Carr, C. Workman, D. E. Smith, J. Hoy, J. Hudson, N. Doong, A. Martin, J. Amin, J. Freund, M. Law, et al. Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy: A Randomized Trial JAMA, July 10, 2002; 288(2): 207 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Chou, M. Haluzik, C. Gregory, K. R. Dietz, C. Vinson, O. Gavrilova, and M. L. Reitman WY14,643, a Peroxisome Proliferator-activated Receptor alpha (PPARalpha ) Agonist, Improves Hepatic and Muscle Steatosis and Reverses Insulin Resistance in Lipoatrophic A-ZIP/F-1 Mice J. Biol. Chem., June 28, 2002; 277(27): 24484 - 24489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Fischer, P. Moller, L. Bindl, I. Melzner, H. Tornqvist, K.-M. Debatin, and M. Wabitsch Induction of Adipocyte Differentiation by a Thiazolidinedione in Cultured, Subepidermal, Fibroblast-Like Cells of an Infant with Congenital Generalized Lipodystrophy J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2384 - 2390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Forman The Antidiabetic Agent LG100754 Sensitizes Cells to Low Concentrations of Peroxisome Proliferator-activated Receptor gamma Ligands J. Biol. Chem., April 5, 2002; 277(15): 12503 - 12506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Mayerson, R. S. Hundal, S. Dufour, V. Lebon, D. Befroy, G. W. Cline, S. Enocksson, S. E. Inzucchi, G. I. Shulman, and K. F. Petersen The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes Diabetes, March 1, 2002; 51(3): 797 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Berger, E. Arioglu Oral, and S. I. Taylor Familial lipodystrophy associated with neurodegeneration and congenital cataracts Neurology, January 8, 2002; 58(1): 43 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bolan, E. A. Oral, P. Gorden, S. Taylor, and S. F. Leitman Intensive, Long-Term Plasma Exchange Therapy for Severe Hypertriglyceridemia in Acquired Generalized Lipoatrophy J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 380 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Nadler and A. D. Attie Please Pass the Chips: Genomic Insights into Obesity and Diabetes J. Nutr., August 1, 2001; 131(8): 2078 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rudich, S. Vanounou, K. Riesenberg, M. Porat, A. Tirosh, I. Harman-Boehm, A. S. Greenberg, F. Schlaeffer, and N. Bashan The HIV Protease Inhibitor Nelfinavir Induces Insulin Resistance and Increases Basal Lipolysis in 3T3-L1 Adipocytes Diabetes, June 1, 2001; 50(6): 1425 - 1431. [Abstract] [Full Text]
|
|
Article
